Once-daily inhaled mosliciguat yields improvements in PH-ILD
Adults with pulmonary hypertension associated with interstitial lung disease receiving once-daily inhaled mosliciguat had a larger decrease in pulmonary vascular resistance at week 16 vs. placebo, according to phase 2 trial topline data.
These findings on mosliciguat (Roivant, Pulmovant), a potential first-in-class sGC activator, were simultaneously presented at the European Respiratory Society International Congress.
“Mosliciguat demonstrated improvements across multiple clinically relevant domains, including hemodynamics, exercise capacity and biomarkers of right ventricular strain,” Parth M.